Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Vincent Van Pesch, Richard Macdonell et al.|JAMA Neurology|2023Cited by 62
Comparative effectiveness of teriflunomide and dimethyl fumarateMathias Due Buron, Melinda Magyari, Thor Petersen et al.|Neurology|2019Cited by 45
Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis RegistryViktoria Papp, Melinda Magyari, Finn Sellebjerg et al.|PLoS ONE|2021Cited by 20
Predictors of treatment switching in the Big Multiple Sclerosis Data NetworkTim Spelman, Tobias Sejbæk, Koen de Gans et al.|Frontiers in Neurology|2023Cited by 9
Patterns and predictors of multiple sclerosis phenotype transitionLuigi Pontieri, Melinda Magyari, Finn Sellebjerg et al.|Brain Communications|2024Cited by 8